Market Overview

Benzinga's Top #PreMarket Losers

Related EXEL
The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines
Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA
What Does Breakthrough Therapy Designation Really Mean For My Company? (Seeking Alpha)
Related CONN
45 Biggest Movers From Yesterday
36 Stocks Moving In Thursday's Mid-Day Session

Exelixis (NASDAQ: EXEL) shares dipped 52.66% to $1.96 in pre-market trading after the company announced its plans to lower around 70% of its workforce. The company reported that its phase 3 pivotal trial of cabozantinib did not meet primary endpoint.

Conns (NASDAQ: CONN) shares declined 25.38% to $33.45 in pre-market trading after the company reported weaker-than-expected second-quarter earnings and cut its full-year forecast.

Elbit Imaging (NASDAQ: EMITF) dropped 2.02% to $3.88 in pre-market trading after falling 3.04% on Friday.

Newmont Mining (NYSE: NEM) fell 1.40% to $26.71 in pre-market trading after the company reached a tentative deal with the Indonesian government over an export dispute.

Finisar (NASDAQ: FNSR) shares dropped 1.33% to $20.04 in pre-market trading. Analysts at Jefferies downgraded Finisar from Buy to Hold and lowered the target price from $25 to $19.

Posted-In: PreMarket LosersNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (CONN + EMITF)

View Comments and Join the Discussion!